| Recruiting | Registry Platform Myelofibrosis and Anemia NCT06976918 | iOMEDICO AG | — |
| Recruiting | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and My NCT07228624 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225 | MPN Research Foundation | — |
| Recruiting | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) NCT06661915 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patien NCT05364762 | City of Hope Medical Center | Phase 2 |
| Completed | Fedratinib in Combination With Nivolumab NCT05393674 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Recruiting | Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera NCT06516406 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis NCT04370301 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis NCT04384692 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplas NCT04339101 | City of Hope Medical Center | Phase 2 |
| Recruiting | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloprolif NCT04282187 | University of Washington | Phase 2 |
| Terminated | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis NCT03303950 | University of Utah | Phase 2 |
| Completed | Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients Wi NCT03426969 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Terminated | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia NCT03195010 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients Wi NCT03118492 | City of Hope Medical Center | Phase 1 |
| Completed | Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in NCT02917096 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced I NCT02528877 | City of Hope Medical Center | Phase 1 |
| Terminated | P1101 in Treating Patients With Myelofibrosis NCT02370329 | Mayo Clinic | Phase 2 |
| Completed | LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essentia NCT02098161 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis NCT02251821 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF NCT01644110 | University of Ulm | Phase 1 / Phase 2 |
| Completed | Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis NCT01732445 | Mayo Clinic | Phase 2 |
| Completed | Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis NCT01731951 | Geron Corporation | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | CC-4047 in Treating Patients With Myelofibrosis NCT00669578 | Mayo Clinic | Phase 1 / Phase 2 |
| Terminated | Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis NCT00630994 | Mayo Clinic | Phase 2 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoi NCT00589563 | City of Hope Medical Center | Phase 2 |
| Terminated | Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating NCT00376519 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients Wit NCT00438958 | The Canadian Blood and Marrow Transplant Group | Phase 3 |
| Completed | Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases NCT00424242 | Northwestern University | EARLY_Phase 1 |
| No Longer Available | Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease NCT00423826 | Barbara Ann Karmanos Cancer Institute | — |
| Completed | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, NCT00445744 | Fred Hutchinson Cancer Center | N/A |
| Terminated | Azacitidine in Treating Patients With Myelofibrosis NCT00381693 | Mayo Clinic | Phase 2 |
| Terminated | Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder NCT00722254 | University of Utah | — |
| Completed | Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic NCT00611351 | University of Nebraska | Phase 2 |
| Completed | Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia NCT00445900 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Decitabine in Treating Patients With Myelofibrosis NCT00095784 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients W NCT00589602 | The Cleveland Clinic | Phase 2 |